ReproNovo, a biotechnology company specializing in reproductive medicine, has raised $65 million to advance two drugs it thinks could help address fertility issues in men and women.

ReproNovo是一家专注于生殖医学的生物技术公司，该公司已经筹集了6500万美元，用于推进两种药物的研发，这些药物有望帮助解决男性和女性的生育问题。

The Switzerland-based firm plans to use the new funds to run Phase 2 clinical trials of the drugs. The first, called leflutrozole, is designed to treat infertility in men with low testosterone, while the second, nolasiban, will be studied in women with a gynecological disorder called adenomyosis and as an adjunctive therapy alongside assisted reproductive technologies..

总部位于瑞士的公司计划使用新的资金来运行这些药物的第二阶段临床试验。第一个名为左旋氟曲唑，用于治疗睾酮水平较低的男性不育症，而第二个药物诺拉西班将被研究用于治疗女性的腺肌症，并作为辅助生殖技术的辅助疗法。

“We are here to fill the critical gaps for patients in reproductive medicine and women’s health,” Jean Maire Duvall, CEO and co-founder of ReproNovo, told BioPharma Dive.

“我们在这里为生殖医学和女性健康领域的患者填补关键空白，”ReproNovo首席执行官兼联合创始人珍·玛丽·杜瓦尔向《生物制药潜水》表示。

Founded in 2021, ReproNovo gained rights to the candidates through licensing deals with Mereo BioPharma and ObsEva, respectively.

ReproNovo 成立于2021年，通过与 Mereo BioPharma 和 ObsEva 的许可协议分别获得了这些候选药物的权利。

Leflutrozole is a small molecule that works by blocking an enzyme called aromatase. This effect, ReproNovo says, could help stabilize levels of testosterone and address male infertility.

来氟曲唑是一种通过阻断一种叫做芳香化酶的酶起作用的小分子。ReproNovo 表示，这种效果可能有助于稳定睾酮水平并解决男性不育问题。

Some research

一些研究

has raised concerns about declines in male reproductive health, as fertility rates among women in the U.S.

引发了人们对男性生殖健康下降的担忧，因为美国女性的生育率

have also fallen

也已经下降

.

。

Although infertility

虽然不孕不育

impacts

影响

both

两者都

men and women, the

男人和女人，

pressure and responsibility

压力与责任

for solving the issue often falls on the woman. “We’d like to offer an alternative where the male could be treated directly,” said Duvall.

解决这个问题的责任往往落在女性身上。杜瓦尔表示：“我们想提供一个男性可以直接接受治疗的替代方案。”

Nolasiban blocks oxytocin receptors, which ReproNovo sees as potentially helpful in managing adenomyosis, a condition where endometrial tissue grows in the uterine walls. Adenomyosis can cause similar symptoms as endometriosis, such as pelvic pain and heavy menstrual bleeding. The condition often

诺拉斯班阻断催产素受体，ReproNovo认为这可能有助于管理子宫腺肌症，这是一种子宫内膜组织在子宫壁内生长的病症。子宫腺肌症会引起类似于子宫内膜异位症的症状，例如盆腔疼痛和月经量过多。该情况常常

occurs

发生

in women between the ages of 35 to 50. There are no drugs specifically approved to treat it.

35至50岁之间的女性。目前尚无专门批准用于治疗该病的药物。

ReproNovo is also studying whether nolasiban can improve embryo implantation by reducing uterine contractility and enhancing blood flow amid embryo transfer during in vitro fertilization. While other treatments are

ReproNovo 还在研究诺拉西班是否可以通过降低子宫收缩性和增强体外受精过程中胚胎移植时的血流来改善胚胎着床。尽管其他治疗方法

available

可用的

and in

并且在

development

开发

to increase the chances of IVF success, none are approved to support embryo implantation specifically, the company said.

该公司表示，为了增加体外受精的成功几率，没有一种方法被批准专门用于支持胚胎着床。

The Series A funding round was led by Jeito Capital and co-led by AXA IM Alts and ReproNovo’s founding investor M Ventures, the venture arm of Merck KGaA. Ysios Capital and Alsa Ventures also participated.

A轮融资由Jeito Capital领投，AXA IM Alts和ReproNovo的创始投资者Merck KGaA的风险投资部门M Ventures共同领投。Ysios Capital和Alsa Ventures也参与了投资。